Anna Sundlöv
1 – 15 of 35
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Retrospective evaluation of the predictive value of tumour burden at baseline [
68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.
(
- Contribution to journal › Article
-
Mark
Relationship Between Absorbed Dose and Response in Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE
(
- Contribution to journal › Article
-
Mark
Optimal follow-up with somatostatin receptor PET/CT imaging in patients with small intestinal neuroendocrine tumours
2024) In Journal of Neuroendocrinology(
- Contribution to journal › Article
- 2023
-
Mark
Phase II study of everolimus and temozolomide as first-line treatment in metastatic high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Nordic 2023 guidelines for the diagnosis and treatment of lung neuroendocrine neoplasms
(
- Contribution to journal › Scientific review
-
Mark
Germline pathogenic variants in patients with high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
AI-based quantification of whole-body tumour burden on somatostatin receptor PET/CT
(
- Contribution to journal › Article
- 2022
-
Mark
The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
(
- Contribution to journal › Article
-
Mark
Dosimetric quantities of neuroendocrine tumors over treatment cycles with 177Lu-DOTA-TATE
(
- Contribution to journal › Article
-
Mark
Relationship between somatostatin receptor expressing tumour volume and health-related quality of life in patients with metastatic GEP-NET
(
- Contribution to journal › Article
-
Mark
Phase II trial demonstrates the efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE treatment of NET patients
(
- Contribution to journal › Article
-
Mark
Increased risk of Graves´ophthalmopathy in patients with increasing TRAb after radioiodine treatment and the impact of CTLA4 on TRAb titres
(
- Contribution to journal › Article
-
Mark
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
(
- Contribution to journal › Article
- 2021
-
Mark
Peptide Receptor Radionuclide Therapy – Prospects for Personalised Treatment
(
- Contribution to journal › Article
-
Mark
Pituitary function after high-dose 177Lu-DOTATATE therapy and long-term follow-up
(
- Contribution to journal › Article